Neurocrine Biosciences CEO Kyle Gano Acquires 8,117 Shares via PRSU Vesting
NEUROCRINE BIOSCIENCES INC
Subscribe to track NBIX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š SEC Form 4 Filing Alert: NEUROCRINE BIOSCIENCES INC ($NBIX) š¤ Insider: Kyle Gano (Chief Executive Officer, Director) š Transaction Date: September 11, 2026 š Transaction Type: PRSU Vesting & Tax Withholding š¹ Shares Acquired: 8,117 shares ($0.00) š» Shares Withheld for Taxes: 4,380 shares @ $156.22 ($684,243.60) š Post-Transaction Beneficial Ownership: 154,728 shares ā ļø Significance: Low (Routine performance RSU vesting with standard tax withholding)
Comprehensive Analysis
Executive Summary
On September 15, 2026, Neurocrine Biosciences, Inc. ($NBIX) filed a Form 4 detailing equity transactions by Chief Executive Officer and Director Kyle Gano executed on September 11, 2026. The filing reports the vesting of Performance Restricted Stock Units (PRSUs) alongside mandatory tax withholding dispositions, resulting in a net increase in beneficial ownership of 3,737 shares.
Transaction Breakdown
- PRSU Vesting (Code A):
- Tranche 1: 6,275 shares acquired at $0.00.
- Tranche 2: 1,842 shares acquired at $0.00.
- Total Acquired: 8,117 shares.
- Tax Withholding (Code F):
- Tranche 1: 3,386 shares withheld at $156.22 per share ($528,960.92).
- Tranche 2: 994 shares withheld at $156.22 per share ($155,282.68).
- Total Withheld: 4,380 shares ($684,243.60 total value).
Ownership & Context
- Following these transactions, Dr. Gano directly holds 154,728 shares of NBIX common stock (which includes 176 shares acquired via the 2018 Employee Stock Purchase Plan).
- Significance Assessment: Low. The reported events represent non-discretionary equity vesting based on the certification of predefined performance metrics and standard company tax withholding, rather than open-market buying or selling.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.